Sep 11, 2023
Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development
Evaxion has achieved a groundbreaking milestone in vaccine discovery with the validation of its AI-powered vaccine discovery platform, EDEN.
Aug 29, 2023
Evaxion announces Executive Management Changes to strengthen the AI-strategy
Evaxion has hired a new Chief Executive Officer (“CEO”) to accelerate the strategic development and execution of the vast business opportunities at hand after having matured the Company’s AI platforms over the past 15 years.
Aug 2, 2023
Evaxion announces financing commitments totaling up to USD 20 million with Global Growth Holding Limited
Evaxion announced that it has entered into a binding agreement for a financing of up to USD 20 million with Global Growth Holding Limited (GGHL), a leading Dubai-based financial institution specialized in providing flexible equity-linked financings.
Jun 3, 2023
Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial
Evaxion's EVX-01 met its primary endpoints of safety and tolerability as positive clinical responses were reported.